Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Steroid dealers using social media and beauty salons to sell cheap Chinese copies of weight-loss drugs, experts warn ...

Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P ...

Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards ...